In a recent appearance on Schwab Network's the Trading 360 with Sam Vadas, Chris Wang provided expert insights on another busy earnings week with analysis on Palantir and Shopify.

Monday: Palantir – high risk, high reward

  • They have accelerated revenue growth for 6 quarters in a row from 12% to 39%; analysts estimates are for 38% this quarter; but potential revenue deceleration going forward; revenue guidance is going to be key because this stock is priced to perfection at over 100x price to sales
  • This quarter will be likely ok but the risk/reward is starting to skew more to the downside; unless AI can deliver sustainable 40% sales which obviously gets more difficult when Palantir closes in a $1B quarterly/revenue rates.
  • Palantir is an AI darling for good reason. They are delivering on AI promises and customers are able to deploy and see results in short order. AIG expects the implementation of AI underwriting to double their revenue CAGR from 10 to 20% over the next 5 years!

Tuesday: Caterpillar – macro play on accelerating global growth

  • Manufacturing has been on a cyclical downdraft with Cat seeing revenue declines for 5 straight quarters
  • GDP growth is accelerating globally; and this should be a positive for CAT;
  • Investors will be seeking clarity on Cat’s backlog which should show positive signs of the manufacturing recession coming to an end
  • In recent years, Cat has focused on developing more emphasis on services and deepening its presence in power gen and on-site power solutions (important for data centers).

Wednesday: consumer; MCD, UBER, DIS, SHOP, ABNB, DASH

  • The one to watch is Shopify. The street is looking for 24% revenue growth. Last week, Amazon’s retail business blew away expectations. Shopify should show a continuation of resilient consumer spending. And with lower taxes in 2026, the consumer position will only get better in the months ahead. Stay bullish consumer spending. Shopify continues to innovate on their platform and is widening its moat vs the competition; also making progress in enterprise as a key growth driver

Wednesday NVO; Thursday LLY

NVO already aggressively cut their GLP-1 estimates; all eyes will be on Lilly to see if their trends are any better; I believe it’s a really interesting time to look at Novo as sentiment may have skewed too bearish. It is trading at just 10x forward PE – this is a historic low valuation for a company with a franchise in diabetes and obesity – neither of these diseases are going away. Pricing pressure is concern; but Novo has a history of success; estimates have come down by 10% for 2026 and 2027 – however estimates are still for 10%+ EPS growth